Viewing Study NCT00522457


Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2025-12-28 @ 1:42 PM
Study NCT ID: NCT00522457
Status: TERMINATED
Last Update Posted: 2011-04-29
First Post: 2007-08-28
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Sponsor: Neovii Biotech
Organization: